Duncan T Njenda1,2, Shambhu G Aralaguppe1, Kamalendra Singh1,3,4, Rohit Rao4, Anders Sönnerborg1,5, Stefan G Sarafianos3,4,6, Ujjwal Neogi1. 1. Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institutet, Huddinge, Stockholm, Sweden. 2. Division of Medical Virology, Department of Pathology, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa. 3. Department of Molecular Microbiology and Immunology, University of Missouri, Columbia, MO, USA. 4. Bond Life Sciences Center, University of Missouri, Columbia, MO, USA. 5. Division of Infectious Diseases, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden. 6. Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.
Abstract
Objectives: 4'-Ethnyl-2'-fluoro-2'-deoxyadenosine (EFdA) is a novel translocation-defective reverse transcriptase inhibitor. We investigated the virological and biochemical inhibitory potentials of EFdA against a broad spectrum of subtype-specific chimeric viruses and compared it with tenofovir alafenamide, nevirapine, efavirenz, rilpivirine and etravirine. Methods: pNL4.3 chimeric viruses encoding gag-pol from treatment-naive patients (n = 24) and therapy-failure patients (n = 3) and a panel of reverse transcriptase inhibitor-resistant strains (n = 7) were used to compare the potency of reverse transcriptase inhibitor drugs. The phenotypic drug susceptibility assay was performed using TZM-bl cells. In vitro inhibition assays were done using patient-derived reverse transcriptase. IC50 values of NNRTIs were calculated using a PicoGreen-based spectrophotometric assay. Steady-state kinetics were used to determine the apparent binding affinity (Km.dNTP) of triphosphate form of EFdA (EFdA-TP) and dATP. Results: Among the chimeric treatment-naive viruses, EFdA had an ex vivo antiretroviral activity [median (IQR) EC50 = 1.4 nM (0.6-2.1 nM)] comparable to that of tenofovir alafenamide [1.6 nM (0.5-3.6 nM)]. Subtype-specific differences were found for etravirine (P = 0.004) and rilpivirine (P = 0.017), where HIV-1C had the highest EC50 values. EFdA had a greater comparative efficiency [calculated by dividing the efficiency of monophosphate form of EFdA (EFdA-MP) incorporation (kcat.EFdA-TP/Km.EFdA-TP) over the efficiency of dATP incorporation (kcat.dATP/Km.dATP)] compared with the natural substrate dATP, with a fold change of between 1.6 and 3.2. Ex vivo analysis on reverse transcriptase inhibitor-resistant strains showed EFdA to have a higher potency. Despite the presence of rilpivirine DRMs, some non-B strains showed hypersusceptibility to rilpivirine. Conclusions: Our combined virological and biochemical data suggest that EFdA inhibits both WT and reverse transcriptase inhibitor-resistant viruses efficiently in a subtype-independent manner. In contrast, HIV-1C is least susceptible to etravirine and rilpivirine.
Objectives:4'-Ethnyl-2'-fluoro-2'-deoxyadenosine (EFdA) is a novel translocation-defective reverse transcriptase inhibitor. We investigated the virological and biochemical inhibitory potentials of EFdA against a broad spectrum of subtype-specific chimeric viruses and compared it with tenofovir alafenamide, nevirapine, efavirenz, rilpivirine and etravirine. Methods: pNL4.3 chimeric viruses encoding gag-pol from treatment-naive patients (n = 24) and therapy-failure patients (n = 3) and a panel of reverse transcriptase inhibitor-resistant strains (n = 7) were used to compare the potency of reverse transcriptase inhibitor drugs. The phenotypic drug susceptibility assay was performed using TZM-bl cells. In vitro inhibition assays were done using patient-derived reverse transcriptase. IC50 values of NNRTIs were calculated using a PicoGreen-based spectrophotometric assay. Steady-state kinetics were used to determine the apparent binding affinity (Km.dNTP) of triphosphate form of EFdA (EFdA-TP) and dATP. Results: Among the chimeric treatment-naive viruses, EFdA had an ex vivo antiretroviral activity [median (IQR) EC50 = 1.4 nM (0.6-2.1 nM)] comparable to that of tenofovir alafenamide [1.6 nM (0.5-3.6 nM)]. Subtype-specific differences were found for etravirine (P = 0.004) and rilpivirine (P = 0.017), where HIV-1C had the highest EC50 values. EFdA had a greater comparative efficiency [calculated by dividing the efficiency of monophosphate form of EFdA (EFdA-MP) incorporation (kcat.EFdA-TP/Km.EFdA-TP) over the efficiency of dATP incorporation (kcat.dATP/Km.dATP)] compared with the natural substrate dATP, with a fold change of between 1.6 and 3.2. Ex vivo analysis on reverse transcriptase inhibitor-resistant strains showed EFdA to have a higher potency. Despite the presence of rilpivirine DRMs, some non-B strains showed hypersusceptibility to rilpivirine. Conclusions: Our combined virological and biochemical data suggest that EFdA inhibits both WT and reverse transcriptase inhibitor-resistant viruses efficiently in a subtype-independent manner. In contrast, HIV-1C is least susceptible to etravirine and rilpivirine.
Authors: Maya Balamane; Vici Varghese; George L Melikian; W Jeffrey Fessel; David A Katzenstein; Robert W Shafer Journal: Antimicrob Agents Chemother Date: 2012-06-04 Impact factor: 5.191
Authors: Ujjwal Neogi; Kamalendra Singh; Shambhu G Aralaguppe; Leonard C Rogers; Duncan T Njenda; Stefan G Sarafianos; Bo Hejdeman; Anders Sönnerborg Journal: AIDS Date: 2018-02-20 Impact factor: 4.177
Authors: Paul A J Janssen; Paul J Lewi; Eddy Arnold; Frits Daeyaert; Marc de Jonge; Jan Heeres; Luc Koymans; Maarten Vinkers; Jérôme Guillemont; Elisabeth Pasquier; Mike Kukla; Don Ludovici; Koen Andries; Marie-Pierre de Béthune; Rudi Pauwels; Kalyan Das; Art D Clark; Yulia Volovik Frenkel; Stephen H Hughes; Bart Medaer; Fons De Knaep; Hilde Bohets; Fred De Clerck; Ann Lampo; Peter Williams; Paul Stoffels Journal: J Med Chem Date: 2005-03-24 Impact factor: 7.446
Authors: Atsuko Hachiya; Aaron B Reeve; Bruno Marchand; Eleftherios Michailidis; Yee Tsuey Ong; Karen A Kirby; Maxwell D Leslie; Shinichi Oka; Eiichi N Kodama; Lisa C Rohan; Hiroaki Mitsuya; Michael A Parniak; Stefan G Sarafianos Journal: Antimicrob Agents Chemother Date: 2013-06-24 Impact factor: 5.191
Authors: Eleftherios Michailidis; Bruno Marchand; Eiichi N Kodama; Kamlendra Singh; Masao Matsuoka; Karen A Kirby; Emily M Ryan; Ali M Sawani; Eva Nagy; Noriyuki Ashida; Hiroaki Mitsuya; Michael A Parniak; Stefan G Sarafianos Journal: J Biol Chem Date: 2009-12-18 Impact factor: 5.157
Authors: Kalyan Das; Arthur D Clark; Paul J Lewi; Jan Heeres; Marc R De Jonge; Lucien M H Koymans; H Maarten Vinkers; Frederik Daeyaert; Donald W Ludovici; Michael J Kukla; Bart De Corte; Robert W Kavash; Chih Y Ho; Hong Ye; Mark A Lichtenstein; Koen Andries; Rudi Pauwels; Marie-Pierre De Béthune; Paul L Boyer; Patrick Clark; Stephen H Hughes; Paul A J Janssen; Eddy Arnold Journal: J Med Chem Date: 2004-05-06 Impact factor: 7.446
Authors: K A Sutherland; J Ghosn; J Gregson; J L Mbisa; M L Chaix; I Cohen Codar; J F Delfraissy; C Delaugerre; R K Gupta Journal: J Antimicrob Chemother Date: 2014-09-16 Impact factor: 5.790
Authors: Kevin D McCormick; Kerri J Penrose; Chanson J Brumme; P Richard Harrigan; Raquel V Viana; John W Mellors; Urvi M Parikh; Carole L Wallis Journal: Antimicrob Agents Chemother Date: 2020-04-21 Impact factor: 5.191
Authors: Kyle J Hill; Leonard C Rogers; Duncan T Njenda; Donald H Burke; Stefan G Sarafianos; Anders Sönnerborg; Ujjwal Neogi; Kamalendra Singh Journal: AIDS Date: 2019-03-01 Impact factor: 4.177